Pfizer has released early data from its vaccine trial on kids ages 5 to 11 and it shows a "robust" antibody response.
The drug-maker explained in a press release today that kids in the trial received two shots of a smaller dose than what teens and adults received, and found that the shot was well tolerated and produced the same immune response. Also, side effects were the same as they are for teens and young adults.
The data is being sent to the FDA "as soon as possible" with the expectation of getting emergency approval soon. Children currently make up about 30% of all new COVID cases in the country. (NBC News)